Substance, composition, or device? EPO addresses method of reaching a decision

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Substance, composition, or device? EPO addresses method of reaching a decision

Sponsored by

inspicos-400px recrop.jpg
Patent Health Care Pharmaceuticals Innovation concept. Copy rights patented certified medicine.

While concrete definitions are still lacking, Peter Koefoed of Inspicos says patent applicants seeking protection for second medical uses of products could now find it easier to build their case

Under Article 53(c) of the European Patent Convention (EPC), methods of therapy or surgery for humans and animals are exempted from patentability, as are diagnostic methods carried out on the human or animal body. At the same time, Article 53(c) specifies that this exemption does not apply to products – in particular, substances and compositions – for use in these methods.

Moreover, Article 54(5), by legal fiction, acknowledges novelty of any "substance or composition" for use in such exempted methods that are themselves novel. It can be derived from the wording of the latter provisions that they only apply to a subset of the products mentioned in Article53(c): substances and compositions.

Board of appeal case law has previously sought to establish criteria for determining whether a product is a substance or composition and not a device. These criteria are laid down in the Guidelines for Examination, G-VI, 6.1.1, which states that a product qualifies as a substance or composition if it is the active agent or ingredient in the specific medical use and if the therapeutic effect can be ascribed to its chemical properties (see G 5/83 and T 1758/15).

In decision T 1252/20 (relating to peptides used in cancer treatment by mechanically blocking blood vessels), of February 6 2024, the board saw no basis in the EPC for considering the mode of action of the claimed substance or composition to determine compliance with Article 54(5). The board pointed out that the exempted methods in Article 53(c) are not merely medical methods but also surgery and diagnostic methods. Moreover, the precise mode of action of a product is not always known. The board hence concluded that it is only relevant to consider whether the claimed product is a substance or composition but not to consider its mode of action.

T 1252/20 does not offer a concrete definition of a substance or composition. Nevertheless, applicants may face fewer obstacles when seeking protection at the EPO for second medical uses of products in cases where the claimed product at face value does not have device-like features.

more from across site and SHARED ros bottom lb

More from across our site

While business has been tough, foreign law firms with IP practices that have decided to stay put in China reveal why they are optimistic
Managing IP will host a ceremony in London on April 10 to reveal the winners of the EMEA Awards 2025
The Intellectual Property Judges' Association wrote to the European Commission just days before the proposals were shelved, it can be revealed
Karla Hughes and Adrian Dykes also join the former global IP head as partners in London, while another partner has left for Clifford Chance
A law firm restricting its employees’ use of AI, a leadership change at Siemens, and ‘probably’ the best trademark news Carlsberg could hope for, were among the top talking points
Former USPTO director Vidal, who rejoined Winston & Strawn after leaving the agency, explains why she got involved in an amicus brief related to jury instructions and Section 101
The judgment clarifies that being employed by a company does not necessarily undermine someone’s independence and ability to appear in court
The EU scrapping a controversial FRAND regulation gives the bloc a chance to properly engage with stakeholders to determine an appropriate way forward
Judd Lauter, who helped his client get a copyright registration for a creative work comprising of AI-generated parts, explains how his team obtained the registration
Ali Razai explains why he and his team joined the firm from Knobbe Martens and why he hopes to do ‘even more’ life sciences work
Gift this article